STI 4398
Alternative Names: COVIDTRAP™ protein; STI-4398Latest Information Update: 28 Jul 2024
At a glance
- Originator Sorrento Therapeutics
- Developer Sorrento Therapeutics; University of Texas Medical Branch
- Class Antivirals; Enzymes; Immunoglobulin Fc fragments; Recombinant fusion proteins
- Mechanism of Action ACE modulators; Virus replication inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported COVID 2019 infections
Most Recent Events
- 28 Jul 2024 No recent reports of development identified for preclinical development in COVID-2019-infections in USA
- 28 Jul 2024 No recent reports of development identified for preclinical development in COVID-2019-infections(Prevention) in USA
- 05 Jun 2020 Preclinical trials in COVID-2019 infections (Prevention) in USA (unspecified route) before June 2020 (Sorrento Therapeutics pipeline, June 2020)